Evolent Health, Inc. is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company's platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models. The Company's services include providing its customers, with a population management platform, integrated data and analytics capabilities, pharmacy benefit management (PBM) services and comprehensive health plan administration services. Its value-based operations are empowered and supported by Identifi. Identifi is the Company's technology platform that aggregates and analyzes data, manages care workflows and engages patients.
Industry, Sector and Symbol:
- Sector: Computer and Technology
- Industry: Medical Software & Technology Services
- Sub-Industry: N/A
- Symbol: NYSE:EVH
- CUSIP: N/A
- Web: www.evolenthealth.com
Capitalization:- Market Cap: $1.31736 billion
- Outstanding Shares: 65,822,000
Average Prices:- 50 Day Moving Avg: $24.02
- 200 Day Moving Avg: $22.70
- 52 Week Range: $14.50 - $27.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: Infinity
- P/E Growth: -1.40
Sales & Book Value:- Annual Revenue: $361.53 million
- Price / Sales: 3.14
- Book Value: $13.07 per share
- Price / Book: 1.32
Profitability:- EBIDTA: ($51,150,000.00)
- Net Margins: -17.57%
- Return on Equity: -6.44%
- Return on Assets: -5.13%
Debt:- Debt-to-Equity Ratio: 0.14%
- Current Ratio: 1.89%
- Quick Ratio: 1.89%
Misc:- Average Volume: 1.30 million shs.
- Beta: 1.22
- Short Ratio: 11.19
Frequently Asked Questions for Evolent Health (NYSE:EVH)
What is Evolent Health's stock symbol?
Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."
How were Evolent Health's earnings last quarter?
Evolent Health, Inc (NYSE:EVH) posted its quarterly earnings results on Monday, August, 7th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The firm earned $107.30 million during the quarter, compared to analysts' expectations of $104.45 million. Evolent Health had a negative return on equity of 6.44% and a negative net margin of 17.57%. The business's revenue for the quarter was up 89.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.20) earnings per share. View Evolent Health's Earnings History.
Where is Evolent Health's stock going? Where will Evolent Health's stock price be in 2017?
12 analysts have issued 12 month price targets for Evolent Health's shares. Their forecasts range from $26.00 to $35.00. On average, they expect Evolent Health's share price to reach $30.33 in the next year. View Analyst Ratings for Evolent Health.
What are analysts saying about Evolent Health stock?
Here are some recent quotes from research analysts about Evolent Health stock:
- 1. According to Zacks Investment Research, "Evolent Health, Inc. is involved in the healthcare delivery and payment markets. The company provides technology-enabled services platform for providers to transition their organization in value-based payment models. Evolent Health, Inc. is based in Arlington, Virginia. " (8/10/2017)
- 2. Cantor Fitzgerald analysts commented, "4Q16 results were solid. Adjusted 4Q16 revenue of $90 million (+92.6% y/y) was above consensus expectations of $85.3 million. Revenue included contributions from Valence and Aldera. Revenue growth was driven by contributions from Valence and Aldera and by an increase in the number of lives on the company’s platform. The number of lives grew 181.5% y/y, reaching about 2.0 million lives in 4Q16. EVH also added another 600,000 lives to the platform in January 2017. Adjusted transformation revenue of $12.1 million increased 12% y/y. Transformation revenue can fluctuate quarter-to-quarter due to the timing of customer contracts and the scope of delivery. Adjusted platform and operation revenue of $77.9 million (+116.8%) benefited from an increased number of lives on the platform. Average PMPM was $12.87 in 4Q16 vs. $16.70." (3/1/2017)
Who are some of Evolent Health's key competitors?
Some companies that are related to Evolent Health include Allscripts Healthcare Solutions (MDRX), Omnicell (OMCL), Emis Group Plc (EMIS), Castlight Health, inc. (CSLT), NantHealth (NH), Craneware plc (CRW), Tabula Rasa Healthcare (TRHC), Simulations Plus (SLP), Fluidigm (FLDM), Medical Transcription Billing, Corp. (MTBC), Constellation Healthcare Tech (CHT) and Press Ganey Holdings (PGND).
Who are Evolent Health's key executives?
Evolent Health's management team includes the folowing people:
- Seth Blackley, President
- Frank John Williams, Chief Executive Officer, Director
- Nicholas P. McGrane, Chief Financial Officer
- Thomas Peterson III, Chief Operating Officer
- Charles W. Pomeroy Jr., Chief Technology Officer
- Lydia Stone, Principal Accounting Officer, Corporate Controller
- Jonathan D. Weinberg, General Counsel
- Dave Thornton, Chief Talent Officer
- Steven J. Wigginton, Chief Development Officer
- David Farner, Director
When did Evolent Health IPO?
(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.
Who owns Evolent Health stock?
Evolent Health's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.93%), JPMorgan Chase & Co. (8.78%), Vanguard Group Inc. (6.09%), Riverbridge Partners LLC (4.02%), Blair William & Co. IL (3.79%) and TimesSquare Capital Management LLC (2.43%). Company insiders that own Evolent Health stock include Board Co Advisory, Chad Pomeroy, Cheryl Scott, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Michael D'amato, Nicholas Mcgrane, Seth Blackley, Steve Wigginton, Thomas Peterson III, Tpg Growth Ii Advisors, Inc and Upmc. View Institutional Ownership Trends for Evolent Health.
Who sold Evolent Health stock? Who is selling Evolent Health stock?
Evolent Health's stock was sold by a variety of institutional investors in the last quarter, including TPG Group Holdings SBS Advisors Inc., Marshall Wace North America L.P., Goldman Sachs Group Inc., Gilder Gagnon Howe & Co. LLC, Tygh Capital Management Inc., Peregrine Capital Management LLC, Elk Creek Partners LLC and Dowling & Yahnke LLC. Company insiders that have sold Evolent Health stock in the last year include Board Co Advisory, Chad Pomeroy, Cheryl Scott, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Nicholas Mcgrane, Seth Blackley, Steve Wigginton, Thomas Peterson III, Tpg Growth Ii Advisors, Inc and Upmc. View Insider Buying and Selling for Evolent Health.
Who bought Evolent Health stock? Who is buying Evolent Health stock?
Evolent Health's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Riverbridge Partners LLC, Vanguard Group Inc., Eagle Asset Management Inc., Wells Fargo & Company MN, Castleark Management LLC, Sectoral Asset Management Inc and Russell Investments Group Ltd.. View Insider Buying and Selling for Evolent Health.
How do I buy Evolent Health stock?
Shares of Evolent Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evolent Health's stock price today?
One share of Evolent Health stock can currently be purchased for approximately $17.25.
MarketBeat Community Rating for Evolent Health (NYSE EVH)MarketBeat's community ratings are surveys of what our community members think about Evolent Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Evolent Health (NYSE:EVH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 11 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 3.08) |
| Consensus Price Target: | $30.33 (75.85% upside) |
Analysts' Ratings History for Evolent Health (NYSE:EVH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/9/2017 | Cowen and Company | Reiterated Rating | Outperform | $35.00 -> $33.00 | High |  |
| 8/8/2017 | Robert W. Baird | Set Price Target | Buy | $35.00 | High | |
| 6/19/2017 | Leerink Swann | Reiterated Rating | Outperform | $30.00 -> $32.00 | Low | |
| 4/13/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $28.00 | Low | |
| 3/14/2017 | CIBC | Initiated Coverage | Outperform -> Outperform | | Low | |
| 3/13/2017 | Oppenheimer Holdings, Inc. | Initiated Coverage | Outperform | $28.00 | Low | |
| 3/8/2017 | Goldman Sachs Group, Inc. (The) | Upgrade | Buy -> Conviction-Buy | $30.00 | Medium | |
| 3/1/2017 | Cantor Fitzgerald | Reiterated Rating | Buy | $26.00 | N/A | |
| 2/3/2017 | Canaccord Genuity | Reiterated Rating | Buy | $31.00 | N/A | |
| 1/13/2017 | Wells Fargo & Company | Upgrade | Market Perform -> Outperform | | N/A | |
| 10/28/2016 | J P Morgan Chase & Co | Initiated Coverage | Overweight | $30.00 | N/A | |
| 9/30/2016 | William Blair | Reiterated Rating | Outperform | | N/A | |
| 8/5/2016 | FBR & Co | Boost Price Target | Outperform | $24.00 -> $26.00 | N/A | |
(Data available from 8/17/2015 forward)
Earnings History for Evolent Health (NYSE:EVH)Earnings History by Quarter for Evolent Health (NYSE EVH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2017 | Q2 2017 | ($0.13) | ($0.13) | $104.45 million | $107.30 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.15) | ($0.26) | $104.38 million | $106.80 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.20) | ($0.35) | $84.98 million | $88.00 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.13) | ($0.26) | $58.35 million | $60.20 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.16) | ($0.12) | $51.96 million | $56.50 million | View | N/A | |
| 5/12/2016 | Q116 | ($0.19) | ($0.16) | $47.40 million | $49.50 million | View | Listen | |
| 2/25/2016 | Q415 | ($0.21) | ($0.05) | $43.73 million | $46.70 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.21) | ($0.16) | $42.51 million | $43.30 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.37) | ($1.00) | $157.50 million | $36.50 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Evolent Health (NYSE:EVH)2017 EPS Consensus Estimate: ($0.24)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q3 2017 | 2 | ($0.07) | ($0.07) | ($0.07) |
| Q4 2017 | 3 | ($0.09) | ($0.04) | ($0.06) |
| Q1 2018 | 1 | ($0.05) | ($0.05) | ($0.05) |
(Data provided by Zacks Investment Research)
Dividend History for Evolent Health (NYSE:EVH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Evolent Health (NYSE:EVH)Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 68.08%
Insider Trades by Quarter for Evolent Health (NYSE:EVH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/3/2017 | Frank J. Williams | CEO | Sell | 16,300 | $23.73 | $386,799.00 | |
| 8/1/2017 | Steve Wigginton | CEO | Sell | 6,000 | $24.64 | $147,840.00 | |
| 7/24/2017 | Thomas Peterson III | COO | Sell | 40,540 | $26.00 | $1,054,040.00 | |
| 7/10/2017 | Nicholas Mcgrane | CFO | Sell | 1,667 | $25.42 | $42,375.14 | |
| 7/6/2017 | Frank J. Williams | CEO | Sell | 16,300 | $24.76 | $403,588.00 | |
| 7/3/2017 | Steve Wigginton | CEO | Sell | 6,000 | $25.07 | $150,420.00 | |
| 6/28/2017 | Tpg Growth Ii Advisors, Inc. | Insider | Sell | 4,279,325 | $25.87 | $110,706,137.75 | |
| 6/15/2017 | Seth Blackley | President | Sell | 15,000 | $25.22 | $378,300.00 | |
| 6/12/2017 | Nicholas Mcgrane | CFO | Sell | 1,667 | $24.58 | $40,974.86 | |
| 6/7/2017 | Nicholas Mcgrane | CFO | Sell | 10,495 | $26.95 | $282,840.25 | |
| 6/6/2017 | Kenneth A. Samet | Director | Sell | 4,000 | $25.75 | $103,000.00 | |
| 6/6/2017 | Steve Wigginton | CEO | Sell | 959 | $25.75 | $24,694.25 | |
| 5/19/2017 | Cheryl Scott | Director | Sell | 5,477 | $23.51 | $128,764.27 | |
| 5/19/2017 | Frank J. Williams | CEO | Sell | 114,865 | $24.30 | $2,791,219.50 | |
| 5/19/2017 | Jonathan Weinberg | General Counsel | Sell | 17,230 | $24.30 | $418,689.00 | |
| 5/19/2017 | Nicholas Mcgrane | CFO | Sell | 47,508 | $24.30 | $1,154,444.40 | |
| 5/19/2017 | Thomas Peterson III | COO | Sell | 57,433 | $24.30 | $1,395,621.90 | |
| 5/19/2017 | Tpg Growth Ii Advisors, Inc. | Insider | Sell | 3,081,760 | $24.30 | $74,886,768.00 | |
| 5/19/2017 | Upmc | Major Shareholder | Sell | 2,333,333 | $24.30 | $56,699,991.90 | |
| 5/15/2017 | Seth Blackley | President | Sell | 15,000 | $25.00 | $375,000.00 | |
| 5/15/2017 | Thomas Peterson III | COO | Sell | 83,108 | $24.99 | $2,076,868.92 | |
| 5/10/2017 | Nicholas Mcgrane | Insider | Sell | 1,667 | $24.28 | $40,474.76 | |
| 5/10/2017 | Thomas Peterson III | COO | Sell | 18,604 | $25.00 | $465,100.00 | |
| 5/4/2017 | Frank J Williams | CEO | Sell | 16,300 | $23.55 | $383,865.00 | |
| 5/3/2017 | Jonathan Weinberg | General Counsel | Sell | 15,000 | $23.85 | $357,750.00 | |
| 5/1/2017 | Steve Wigginton | CEO | Sell | 6,000 | $23.10 | $138,600.00 | |
| 5/1/2017 | Upmc | Major Shareholder | Sell | 403,644 | $19.53 | $7,883,167.32 | |
| 4/19/2017 | Nicholas Mcgrane | CFO | Sell | 1,667 | $22.52 | $37,540.84 | |
| 4/17/2017 | Seth Blackley | President | Sell | 15,000 | $21.48 | $322,200.00 | |
| 4/6/2017 | Frank J Williams | CEO | Sell | 16,300 | $22.03 | $359,089.00 | |
| 4/3/2017 | Steve Wigginton | CEO | Sell | 6,000 | $23.15 | $138,900.00 | |
| 3/31/2017 | Upmc | Major Shareholder | Sell | 2,690,961 | $19.53 | $52,554,468.33 | |
| 3/30/2017 | Seth Blackley | President | Sell | 15,000 | $21.19 | $317,850.00 | |
| 3/28/2017 | Board Co Advisory | Major Shareholder | Sell | 2,118,078 | $19.53 | $41,366,063.34 | |
| 3/24/2017 | Nicholas Mcgrane | CFO | Sell | 7,034 | $22.50 | $158,265.00 | |
| 1/30/2017 | Seth Blackley | President | Sell | 15,000 | $17.58 | $263,700.00 | |
| 1/17/2017 | Seth Blackley | President | Sell | 30,000 | $17.98 | $539,400.00 | |
| 11/14/2016 | Michael D'amato | Director | Buy | 10,000 | $17.18 | $171,800.00 | |
| 9/22/2016 | Board Co Advisory | Major Shareholder | Sell | 317,712 | $22.50 | $7,148,520.00 | |
| 9/14/2016 | Board Co Advisory | Major Shareholder | Sell | 1,936,529 | $22.50 | $43,571,902.50 | |
| 9/14/2016 | Chad Pomeroy | Insider | Sell | 55,180 | $21.54 | $1,188,577.20 | |
| 9/14/2016 | Frank J Williams | CEO | Sell | 251,481 | $21.54 | $5,416,900.74 | |
| 9/14/2016 | Jonathan Weinberg | General Counsel | Sell | 10,339 | $21.54 | $222,702.06 | |
| 9/14/2016 | Nicholas Mcgrane | CFO | Sell | 21,205 | $21.54 | $456,755.70 | |
| 9/14/2016 | Seth Blackley | President | Sell | 167,672 | $21.54 | $3,611,654.88 | |
| 9/14/2016 | Thomas Peterson III | COO | Sell | 72,827 | $21.54 | $1,568,693.58 | |
| 6/10/2015 | Gary Piefer | Insider | Buy | 2,000 | $17.00 | $34,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Evolent Health (NYSE:EVH)
Latest Headlines for Evolent Health (NYSE:EVH)
| Source: |
|
| Date | Headline |
|---|
 | Q3 2017 Earnings Estimate for Evolent Health, Inc Issued By William Blair (EVH)
www.americanbankingnews.com - August 17 at 8:22 AM |
 | See what the IHS Markit Score report has to say about Evolent Health Inc.
finance.yahoo.com - August 12 at 5:43 PM |
| Evolent Health, Inc (NYSE:EVH) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - August 12 at 3:34 PM |
| FY2017 EPS Estimates for Evolent Health, Inc (EVH) Reduced by Oppenheimer Holdings
www.americanbankingnews.com - August 11 at 12:02 PM |
| Q3 2017 EPS Estimates for Evolent Health, Inc (NYSE:EVH) Decreased by Analyst
www.americanbankingnews.com - August 11 at 9:34 AM |
| Evolent Health, Inc (NYSE:EVH) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - August 10 at 7:46 PM |
| Evolent Health, Inc. :EVH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 7:45 PM |
| Edited Transcript of EVH earnings conference call or presentation 7-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 4:23 AM |
| Evolent Health, Inc. Announces Pricing of Public Offering of Class A Common Stock
finance.yahoo.com - August 8 at 11:19 PM |
 | Evolent Health's (EVH) CEO Frank Williams on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 6:15 PM |
 | Oversold Conditions For Evolent Health (EVH) - Nasdaq
www.nasdaq.com - August 8 at 6:15 PM |
| Investor Network: Evolent Health Inc. to Host Earnings Call
finance.yahoo.com - August 8 at 6:15 PM |
| Evolent Health stock falls on bigger loss, new stock offering
finance.yahoo.com - August 8 at 6:15 PM |
 | Why Evolent Health, Inc. Is Plunging Today
www.fool.com - August 8 at 1:32 PM |
| Evolent Health, Inc (EVH) Given a $35.00 Price Target at Robert W. Baird
www.americanbankingnews.com - August 8 at 10:06 AM |
 | Evolent Health Announces Second Quarter 2017 Results - PR Newswire (press release)
www.prnewswire.com - August 8 at 4:46 AM |
 | Evolent Health (EVH) Plans $175M Offering of Class A Common Stock - StreetInsider.com
www.streetinsider.com - August 8 at 4:46 AM |
| Evolent Health, Inc (EVH) Posts Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - August 7 at 9:16 PM |
| Evolent Health (EVH) Plans $175M Offering of Class A Common Stock
www.streetinsider.com - August 7 at 6:42 PM |
| Evolent Health Announces Second Quarter 2017 Results
finance.yahoo.com - August 7 at 6:42 PM |
| Evolent Health Partners with Crystal Run Healthcare to Power Its New York-Based Provider-Sponsored Health Plan
finance.yahoo.com - August 7 at 6:42 PM |
| Evolent Health, Inc. Announces Proposed Public Offering of Class A Common Stock
finance.yahoo.com - August 7 at 6:42 PM |
| Evolent Health reports 2Q loss
finance.yahoo.com - August 7 at 6:42 PM |
| Head-To-Head Contrast: Fluidigm Corporation (FLDM) vs. Evolent Health (EVH)
www.americanbankingnews.com - August 6 at 10:30 AM |
| Zacks: Analysts Expect Evolent Health, Inc (NYSE:EVH) Will Post Quarterly Sales of $104.54 Million
www.americanbankingnews.com - August 5 at 11:10 AM |
| Evolent Health, Inc (NYSE:EVH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 5 at 10:48 AM |
| Frank J. Williams Sells 16,300 Shares of Evolent Health, Inc (NYSE:EVH) Stock
www.americanbankingnews.com - August 4 at 8:22 PM |
| Insider Selling: Evolent Health, Inc (NYSE:EVH) CEO Sells 6,000 Shares of Stock
www.americanbankingnews.com - August 3 at 8:40 PM |
| Evolent Health, Inc (NYSE:EVH) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - August 3 at 8:08 AM |
| Evolent Health, Inc. Announces Revised Second Quarter 2017 Operating Results and Conference Call Date
finance.yahoo.com - July 31 at 6:11 PM |
| Evolent Health, Inc. breached its 50 day moving average in a Bearish Manner : EVH-US : July 28, 2017
finance.yahoo.com - July 28 at 4:32 PM |
| Evolent Health, Inc (NYSE:EVH) COO Thomas Peterson III Sells 40,540 Shares
www.americanbankingnews.com - July 26 at 7:58 PM |
| Contrasting Fluidigm Corporation (FLDM) and Evolent Health (EVH)
www.americanbankingnews.com - July 26 at 8:32 AM |
| Evolent Health, Inc. to Release Second Quarter 2017 Operating Results and Host Conference Call on Tuesday, August 8, 2017
finance.yahoo.com - July 25 at 6:42 PM |
| Head-To-Head Analysis: Simulations Plus (SLP) vs. Evolent Health (NYSE:EVH)
www.americanbankingnews.com - July 21 at 12:06 PM |
| Evolent Health Inc (EVH) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - July 16 at 3:22 PM |
| $104.54 Million in Sales Expected for Evolent Health, Inc (EVH) This Quarter
www.americanbankingnews.com - July 13 at 10:00 AM |
| Nicholas Mcgrane Sells 1,667 Shares of Evolent Health, Inc (NYSE:EVH) Stock
www.americanbankingnews.com - July 12 at 8:45 PM |
| Evolent Health, Inc (NYSE:EVH) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 11 at 10:48 AM |
| Evolent Health, Inc. – Value Analysis (NYSE:EVH) : July 10, 2017
finance.yahoo.com - July 10 at 6:23 PM |
| Evolent Health, Inc. breached its 50 day moving average in a Bearish Manner : EVH-US : July 7, 2017
finance.yahoo.com - July 8 at 10:38 AM |
| Steve Wigginton Sells 6,000 Shares of Evolent Health, Inc (EVH) Stock
www.americanbankingnews.com - July 6 at 8:05 PM |
| Tpg Growth Ii Advisors, Inc. Sells 4,279,325 Shares of Evolent Health, Inc (EVH) Stock
www.americanbankingnews.com - June 30 at 7:16 PM |
| Evolent Health's (EVH) "Outperform" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - June 28 at 12:40 PM |
 | What The Street Gets Wrong About Evolent Health, Cowen's 'Best Small-Mid Cap Idea' - Benzinga
www.benzinga.com - June 28 at 3:23 AM |
 | Evolent Health (EVH) Is Heading Lower After Secondary Offering
www.rttnews.com - June 24 at 5:26 PM |
| Evolent Health (EVH) Prices 4.5M Follow-On Share Offering - Nasdaq
www.nasdaq.com - June 23 at 5:42 PM |
| Seth Blackley Sells 15,000 Shares of Evolent Health, Inc (EVH) Stock
www.americanbankingnews.com - June 19 at 7:35 PM |
| Evolent Health's (EVH) "Outperform" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - June 19 at 5:38 PM |
| Evolent Health (EVH) PT Raised to $32 at Leerink Partners - StreetInsider.com
www.streetinsider.com - June 19 at 1:23 PM |
Evolent Health (EVH) Chart for Thursday, August, 17, 2017
